Table 3.
Summary of studies evaluating acarbose in dumping syndrome
| Study | n | Treatment | Result |
|---|---|---|---|
| McLoughlin et al.111 | 10 | Acarbose 100 mg single administration prior to OGTT | Improved symptoms and hyperglycaemia and hypoglycaemia during OGTT; reduced rise in plasma levels of gastric inhibitory polypeptide and insulin; no change in gastric emptying rate |
| Gerard et al.108 | 24 | Acarbose 100 mg single administration prior to OGTT | Improved hyperglycaemia and hypoglycaemia during OGTT; reduced rise in plasma levels of insulin; inhibition of glucose-induced suppression of glucagon |
| Lyons et al.110 | 13 | Acarbose 50 mg single administration prior to standard breakfast | Significant attenuation of hyperglycaemia; reduced rise in plasma levels of gastric inhibitory polypeptide, enteroglucagon and insulin; no influence on plasma levels of vasoactive intestinal polypeptide and somatostatin; no significant effect on symptoms |
| Hasegawa et al.109 | 6 | Acarbose 50–100 mg 3 times per day before meals for a month | Attenuation of glucose fluctuations and improvement of dumping syndrome symptoms (uncontrolled) |
| Ozgen et al.113 | 21 | Acarbose 150 mg per day before meals for 2 weeks and 300 mg per day for the remainder of the 3-month treatment period | Reduced early hyperglycaemic and hyperinsulinaemic response; reduced reactive hypoglycaemia |
| Ng et al.12 | 6 | Acarbose 12.5 mg before a meal | Improved postprandial hypoglycaemia |
| De Cunto et al.115 | 4 | Acarbose 25–100 mg before meals | Stabilized postprandial levels of glucose |
| Valderas et al.114 | 8 | Acarbose 100 mg before a meal | Avoided postprandial hypoglycaemia; reduced hyperinsulinaemic response; reduced GLP1 secretion |
| Ritz et al.76 | 8 | Acarbose 50–100 mg, 3 times per day for 6 weeks | Eliminated dumping syndrome symptoms and improved CGM profile |
| Speth et al.107 | 9 | Acarbose 50–100 mg, pectin 4.2 g, acarbose 50 mg plus pectin 4.2 g, placebo, after standard breakfast | Acarbose and acarbose plus pectin inhibited postprandial hyperglycaemia and hypoglycaemia; acarbose plus pectin inhibited hyperinsulinaemia; acarbose, pectin and combination therapy reduced hypoglycaemic symptoms |
CGM, continuous glucose monitoring; GLP1, glucagon-like peptide 1; OGTT, modified oral glucose tolerance test.